FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008049168> ?p ?o ?g. }

• W2008049168 endingPage "841" @default.
• W2008049168 startingPage "830" @default.
• W2008049168 abstract "No AccessJournal of UrologyInvestigative Urology1 Mar 2014Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder Evanguelos Xylinas, Eugene K. Cha, Francesca Khani, Luis A. Kluth, Malte Rieken, Björn G. Volkmer, Richard Hautmann, Rainer Küfer, Yao-Tseng Chen, Marc Zerbib, Mark A. Rubin, Douglas S. Scherr, Shahrokh F. Shariat, and Brian D. Robinson Evanguelos XylinasEvanguelos Xylinas Department of Urology, Weill Cornell Medical College, New York, New York Institut National de la Santé et de la Recherche Médicale U955 Equipe 07, Université Paris-Est Créteil, Créteil, France Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France More articles by this author , Eugene K. ChaEugene K. Cha Department of Urology, Weill Cornell Medical College, New York, New York More articles by this author , Francesca KhaniFrancesca Khani Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author , Luis A. KluthLuis A. Kluth Department of Urology, Weill Cornell Medical College, New York, New York Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany More articles by this author , Malte RiekenMalte Rieken Department of Urology, Weill Cornell Medical College, New York, New York Department of Urology, University Hospital Basel, Basel, Switzerland More articles by this author , Björn G. VolkmerBjörn G. Volkmer Department of Urology, Hospital Kassel, Kassel, Germany More articles by this author , Richard HautmannRichard Hautmann Department of Urology, University Hospital Ulm, Ulm, Germany More articles by this author , Rainer KüferRainer Küfer Department of Urology, Hospital am Eichert, Göppingen, Germany More articles by this author , Yao-Tseng ChenYao-Tseng Chen Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author , Marc ZerbibMarc Zerbib Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France More articles by this author , Mark A. RubinMark A. Rubin Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York Institute for Precision Medicine of Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York More articles by this author , Douglas S. ScherrDouglas S. Scherr Department of Urology, Weill Cornell Medical College, New York, New York More articles by this author , Shahrokh F. ShariatShahrokh F. Shariat Department of Urology, Weill Cornell Medical College, New York, New York Division of Medical Oncology, Weill Cornell Medical College, New York, New York Department of Urology, Medical University of Vienna, Vienna, Austria More articles by this author , and Brian D. RobinsonBrian D. Robinson Department of Urology, Weill Cornell Medical College, New York, New York Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.08.048AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Oncofetal proteins are expressed in the developing embryo. Oncofetal protein expression correlates with the clinical outcome of nonmuscle invasive bladder urothelial carcinoma. IMP3, MAGE-A, glypican-3 and TPBG are oncofetal proteins that have not been well characterized in urothelial carcinoma of the bladder. Materials and Methods: We investigated the expression of these 4 proteins and their association with clinical outcomes using tissue microarrays from 384 consecutive patients treated with radical cystectomy between 1988 and 2003 at 1 academic center. We stained for IMP3, MAGE-A, glypican-3 and TPBG. Univariable and multivariable Cox regression analyses were done to evaluate the association of oncofetal protein expression with disease recurrence and cancer specific mortality. Results: IMP3, MAGE-A, glypican-3 and TPBG were expressed in 39.5%, 45%, 6% and 85% of urothelial bladder carcinomas, respectively. Expression was tumor specific and did not correlate with pathological features except for TPBG. At a median followup of 128 months 176 patients (46%) experienced disease recurrence, 175 (45.5%) had died of the disease and 96 (27.5%) had died of another cause. On univariable analysis IMP3 and MAGE-A expression was associated with an increased risk of disease recurrence (p <0.001 and 0.03) and cancer specific mortality (p = 0.004 and 0.03, respectively). On multivariable Cox regression analysis adjusted for the effects of standard clinicopathological features IMP3 and MAGE-A expression was independently associated with disease recurrence (p = 0.004, HR 1.55, 95% CI 1.15–2.11 and p = 0.02, HR 1.44, 95% CI 1.05–1.99, respectively) but not with cancer specific mortality. Conclusions: Oncofetal proteins are commonly and differentially expressed in urothelial carcinoma of the bladder compared to normal urothelium. IMP3 and MAGE-A expression was associated with disease recurrence and cancer specific mortality but glypican-3 and TPBG expression was not. References 1 : Cancer statistics, 2013. CA Cancer J Clin2013; 63: 11. Google Scholar 2 : Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol2012; 61: 1039. Google Scholar 3 : Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol2006; 176: 2414. Link, Google Scholar 4 : Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol2001; 19: 666. Google Scholar 5 : Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep2012; 13: 122. Google Scholar 6 : Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol2010; 28: 441. Google Scholar 7 : Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol2010; 28: 389. Google Scholar 8 : Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer1990; 61: 89. Google Scholar 9 : MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A2006; 103: 11160. Google Scholar 10 : The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol2005; 18: 1591. Google Scholar 11 : The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin. Int J Oncol2008; 32: 221. Google Scholar 12 : Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res2009; 15: 7012. Google Scholar 13 : IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res2008; 14: 1701. Google Scholar 14 : Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer2012; 107: 116. Google Scholar 15 : Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol2013; 31: 1716. Google Scholar 16 : Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol2012; 61: 854. Google Scholar 17 : High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int2012; 110: E308. Google Scholar 18 : Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res2005; 11: 8055. Google Scholar 19 : Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer2011; 128: 2947. Google Scholar 20 : Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol2006; 50: 1254. Google Scholar 21 : Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer2012; 107: 1826. Google Scholar 22 : E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology2001; 57: 60. Google Scholar 23 : Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol2007; 20: 445. Google Scholar 24 Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol2005; 48: 189. Google Scholar 25 : Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci2009; 100: 1502. Google Scholar 26 Amato RJ and M. Stepankiw: Clinical efficacy of TroVax in the treatment of progressive castration-resistant prostate cancer. Clin Med Insights Oncol 2012; 6: 67. Google Scholar 27 : TroVax(®) vaccine therapy for renal cell carcinoma. Immunotherapy2012; 4: 27. Google Scholar © 2014 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2020) Re: 5-Methylcytosine Promotes Pathogenesis of Bladder Cancer through Stabilizing mRNAsJournal of Urology, VOL. 203, NO. 5, (884-885), Online publication date: 1-May-2020. Volume 191Issue 3March 2014Page: 830-841Supplementary Materials Advertisement Copyright & Permissions© 2014 by American Urological Association Education and Research, Inc.Keywordsurinary bladderurotheliumriskoncofetal antigenscarcinomaMetricsAuthor Information Evanguelos Xylinas Department of Urology, Weill Cornell Medical College, New York, New York Institut National de la Santé et de la Recherche Médicale U955 Equipe 07, Université Paris-Est Créteil, Créteil, France Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France More articles by this author Eugene K. Cha Department of Urology, Weill Cornell Medical College, New York, New York More articles by this author Francesca Khani Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author Luis A. Kluth Department of Urology, Weill Cornell Medical College, New York, New York Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany More articles by this author Malte Rieken Department of Urology, Weill Cornell Medical College, New York, New York Department of Urology, University Hospital Basel, Basel, Switzerland More articles by this author Björn G. Volkmer Department of Urology, Hospital Kassel, Kassel, Germany More articles by this author Richard Hautmann Department of Urology, University Hospital Ulm, Ulm, Germany More articles by this author Rainer Küfer Department of Urology, Hospital am Eichert, Göppingen, Germany More articles by this author Yao-Tseng Chen Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author Marc Zerbib Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France More articles by this author Mark A. Rubin Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York Institute for Precision Medicine of Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York More articles by this author Douglas S. Scherr Department of Urology, Weill Cornell Medical College, New York, New York More articles by this author Shahrokh F. Shariat Department of Urology, Weill Cornell Medical College, New York, New York Division of Medical Oncology, Weill Cornell Medical College, New York, New York Department of Urology, Medical University of Vienna, Vienna, Austria More articles by this author Brian D. Robinson Department of Urology, Weill Cornell Medical College, New York, New York Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2008049168 created "2016-06-24" @default.
• W2008049168 creator A5020529503 @default.
• W2008049168 creator A5021219061 @default.
• W2008049168 creator A5029487621 @default.
• W2008049168 creator A5031734114 @default.
• W2008049168 creator A5035068594 @default.
• W2008049168 creator A5036106560 @default.
• W2008049168 creator A5050255590 @default.
• W2008049168 creator A5053215060 @default.
• W2008049168 creator A5058816521 @default.
• W2008049168 creator A5059654230 @default.
• W2008049168 creator A5073121209 @default.
• W2008049168 creator A5079401169 @default.
• W2008049168 creator A5081063474 @default.
• W2008049168 creator A5088310846 @default.
• W2008049168 date "2014-03-01" @default.
• W2008049168 modified "2023-10-01" @default.
• W2008049168 title "Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder" @default.
• W2008049168 cites W1532787392 @default.
• W2008049168 cites W174462206 @default.
• W2008049168 cites W1976801200 @default.
• W2008049168 cites W1983356813 @default.
• W2008049168 cites W1989399572 @default.
• W2008049168 cites W2006283915 @default.
• W2008049168 cites W2010998369 @default.
• W2008049168 cites W2018410490 @default.
• W2008049168 cites W2032554396 @default.
• W2008049168 cites W2046821528 @default.
• W2008049168 cites W2054173744 @default.
• W2008049168 cites W2059616287 @default.
• W2008049168 cites W2065153594 @default.
• W2008049168 cites W2071457935 @default.
• W2008049168 cites W2077991750 @default.
• W2008049168 cites W2080015838 @default.
• W2008049168 cites W2081547800 @default.
• W2008049168 cites W2090241022 @default.
• W2008049168 cites W2113156769 @default.
• W2008049168 cites W2125486991 @default.
• W2008049168 cites W2128766159 @default.
• W2008049168 cites W2131638796 @default.
• W2008049168 cites W2131711899 @default.
• W2008049168 cites W2161817637 @default.
• W2008049168 cites W2167855391 @default.
• W2008049168 cites W2952699285 @default.
• W2008049168 doi "https://doi.org/10.1016/j.juro.2013.08.048" @default.
• W2008049168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23994370" @default.
• W2008049168 hasPublicationYear "2014" @default.
• W2008049168 type Work @default.
• W2008049168 sameAs 2008049168 @default.
• W2008049168 citedByCount "16" @default.
• W2008049168 countsByYear W20080491682014 @default.
• W2008049168 countsByYear W20080491682015 @default.
• W2008049168 countsByYear W20080491682016 @default.
• W2008049168 countsByYear W20080491682017 @default.
• W2008049168 countsByYear W20080491682018 @default.
• W2008049168 countsByYear W20080491682019 @default.
• W2008049168 countsByYear W20080491682020 @default.
• W2008049168 countsByYear W20080491682022 @default.
• W2008049168 crossrefType "journal-article" @default.
• W2008049168 hasAuthorship W2008049168A5020529503 @default.
• W2008049168 hasAuthorship W2008049168A5021219061 @default.
• W2008049168 hasAuthorship W2008049168A5029487621 @default.
• W2008049168 hasAuthorship W2008049168A5031734114 @default.
• W2008049168 hasAuthorship W2008049168A5035068594 @default.
• W2008049168 hasAuthorship W2008049168A5036106560 @default.
• W2008049168 hasAuthorship W2008049168A5050255590 @default.
• W2008049168 hasAuthorship W2008049168A5053215060 @default.
• W2008049168 hasAuthorship W2008049168A5058816521 @default.
• W2008049168 hasAuthorship W2008049168A5059654230 @default.
• W2008049168 hasAuthorship W2008049168A5073121209 @default.
• W2008049168 hasAuthorship W2008049168A5079401169 @default.
• W2008049168 hasAuthorship W2008049168A5081063474 @default.
• W2008049168 hasAuthorship W2008049168A5088310846 @default.
• W2008049168 hasConcept C121608353 @default.
• W2008049168 hasConcept C126322002 @default.
• W2008049168 hasConcept C126894567 @default.
• W2008049168 hasConcept C142724271 @default.
• W2008049168 hasConcept C143998085 @default.
• W2008049168 hasConcept C193270364 @default.
• W2008049168 hasConcept C207886595 @default.
• W2008049168 hasConcept C2775910329 @default.
• W2008049168 hasConcept C2776869981 @default.
• W2008049168 hasConcept C2777546739 @default.
• W2008049168 hasConcept C2777701055 @default.
• W2008049168 hasConcept C2779134260 @default.
• W2008049168 hasConcept C2780352672 @default.
• W2008049168 hasConcept C3019217517 @default.
• W2008049168 hasConcept C50382708 @default.
• W2008049168 hasConcept C71924100 @default.
• W2008049168 hasConceptScore W2008049168C121608353 @default.
• W2008049168 hasConceptScore W2008049168C126322002 @default.
• W2008049168 hasConceptScore W2008049168C126894567 @default.
• W2008049168 hasConceptScore W2008049168C142724271 @default.
• W2008049168 hasConceptScore W2008049168C143998085 @default.
• W2008049168 hasConceptScore W2008049168C193270364 @default.
• W2008049168 hasConceptScore W2008049168C207886595 @default.
• W2008049168 hasConceptScore W2008049168C2775910329 @default.

• next